Patents by Inventor Ole Hvilsted Olsen

Ole Hvilsted Olsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6960657
    Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: November 1, 2005
    Assignee: Novo Nordisk Healthcare A/G
    Inventors: Egon Persson, Ole Hvilsted Olsen
  • Patent number: 6951878
    Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP?, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: October 4, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
  • Patent number: 6911323
    Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
    Type: Grant
    Filed: September 24, 2003
    Date of Patent: June 28, 2005
    Assignee: Novo Nordisk Healthcare A/G
    Inventors: Egon Persson, Ole Hvilsted Olsen
  • Patent number: 6905683
    Abstract: The invention concerns novel coagulation factor VII variants, wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs; with the proviso that the variant is not FVII(Ala305).
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: June 14, 2005
    Assignee: Novo Nordisk Healthcare A/G
    Inventors: Egon Persson, Ole Hvilsted Olsen
  • Publication number: 20040192602
    Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: September 24, 2003
    Publication date: September 30, 2004
    Inventors: Egon Persson, Ole Hvilsted Olsen
  • Publication number: 20040152633
    Abstract: The invention described herein provides novel human Kunitz-type protease inhibitors; nucleic acids encoding such inhibitors; vectors and host cells comprising such nucleic acids; compositions comprising such inhibitors, cells, and/or nucleic acids; methods of producing such inhibitors, nucleic acids, vectors, compositions, and cells; and methods of inducing, promoting, and/or enhancing a physiological response in a subject by administering to the subject an amount of such an inhibitor, nucleic acid, vector, host cell, and/or composition sufficient to induce such a physiological response.
    Type: Application
    Filed: November 25, 2003
    Publication date: August 5, 2004
    Inventors: Marianne Ulrich Jorgensen, Susanne Bang, Ole Hvilsted Olsen, Lars Christian Petersen
  • Patent number: 6632646
    Abstract: Enzymes produced by mutating the genes for a number of subtilisin proteases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved wash performance in comparison to their wild type parent enzymes. The enzymes are well-suited for use in detergent compositions.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: October 14, 2003
    Assignees: Novozymes A/S, Unilever PLC.
    Inventors: Dorrit Aaslyng, Sven Branner, Sven Hastrup, Leif Nørskov-Lauritsen, Ole Hvilsted Olsen, Merete Simonsen, Eric Casteleijn, Maarten Robert Egmond, Johan Haverkamp, John David Marugg, Arnoldus Theodorus Anthonius Mooren
  • Publication number: 20030170863
    Abstract: The invention concerns novel coagulation factor VII variants, wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs;
    Type: Application
    Filed: May 3, 2001
    Publication date: September 11, 2003
    Inventors: Egon Persson, Ole Hvilsted Olsen
  • Patent number: 6613903
    Abstract: The present invention provides novel thienopyridines, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP, wherein X, R1, R2, R3, and R4 are defined more fully in the description. The compounds are useful in the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: September 2, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Sune Andersen, Thomas Kruse Hansen, Jesper Lau, Niels Peter Hundahl Moller, Ole Hvilsted Olsen, Frank Urban Axe, Farid Bakir, Yu Ge, Daniel Dale Holsworth, Luke Milburn Judge, Michael James Newman, Roy Teruyuki Uyeda, Barry Zvi Shapira
  • Publication number: 20030130191
    Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: October 28, 2002
    Publication date: July 10, 2003
    Inventors: Egon Persson, Ole Hvilsted Olsen
  • Publication number: 20030104978
    Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: September 13, 2001
    Publication date: June 5, 2003
    Inventors: Egon Persson, Ole Hvilsted Olsen
  • Publication number: 20030100740
    Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: November 15, 2002
    Publication date: May 29, 2003
    Inventors: Egon Persson, Ole Hvilsted Olsen
  • Publication number: 20030100075
    Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: September 24, 2002
    Publication date: May 29, 2003
    Inventors: Egon Persson, Ole Hvilsted Olsen
  • Publication number: 20030069267
    Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like.
    Type: Application
    Filed: May 28, 2002
    Publication date: April 10, 2003
    Inventors: Niels Peter Hundahl Moller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
  • Publication number: 20030064979
    Abstract: This invention relates to oxalylamide inhibitors of Protein Tyrosine Phosphatase 1B (PTP1B) and/or T-cell Protein Tyrosine Phosphatase (TC-PTP) and/or Protein Tyrosine Phosphatases (PTPases) having an aspartic acid (Asp) in position 48 (PTP1B numbering, Chernoff et al, Proc Natl Acad Sci USA 87: 2735-2789 (1989)) and a method of inhibiting such PTPases by exposing the enzyme to inhibitor compounds of formula 1 1
    Type: Application
    Filed: June 27, 2002
    Publication date: April 3, 2003
    Inventors: Thomas Kruse Hansen, Ole Hvilsted Olsen, Anders Klarskov Petersen, Jesper Lau, Henrik Sune Andersen, Niels Peter Hundahl Moller
  • Publication number: 20020165398
    Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like.
    Type: Application
    Filed: April 19, 2002
    Publication date: November 7, 2002
    Inventors: Lone Jeppesen, Henrik Sune Andersen, Ole Hvilsted Olsen, Luke Milburn Judge, Daniel Dale Holsworth, Farid Bakir, Frank Urban Axe, Yu Ge
  • Publication number: 20020151561
    Abstract: The present invention provides novel thienopyridines, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP, 1
    Type: Application
    Filed: July 9, 2001
    Publication date: October 17, 2002
    Inventors: Henrik Sune Andersen, Thomas Kruse Hansen, Jesper Lau, Niels Peter Hundahl Moller, Ole Hvilsted Olsen, Frank Urban Axe, Farid Bakir, Yu Ge, Daniel Dale Holsworth, Luke Milburn Judge, Michael James Newman, Roy Teruyuki Uyeda, Barry Zvi Shapira
  • Publication number: 20020099073
    Abstract: The present invention provides novel thienopyridines, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP (TC-PTP), 1
    Type: Application
    Filed: July 9, 2001
    Publication date: July 25, 2002
    Inventors: Henrik Sune Andersen, Thomas Kruse Hansen, Jesper Lau, Niels Peter Hundahl Moller, Ole Hvilsted Olsen, Frank Urban Axe, Farid Bakir, Yu Ge, Daniel Dale Holsworth, Luke Milburn Judge, Michael James Newman, Roy Teruyuki Uyeda, Barry Zvi Shapira
  • Patent number: 6410556
    Abstract: Disclosed are novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP, wherein n, m, X, R1, R2, R3, R4, R5, R6, and R7 are defined more fully in the description. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.
    Type: Grant
    Filed: September 11, 2000
    Date of Patent: June 25, 2002
    Assignees: Novo Nordisk A/S, Ontogen Corporation
    Inventors: Henrik Sune Andersen, Thomas Kruse Hansen, Jesper Lau, Niels Peter Hundahl Møller, Ole Hvilsted Olsen, Frank Urban Axe, Yu Ge, Daniel Dale Holsworth, Todd Kevin Jones, Luke Milburn Judge, Wiliam Charles Ripka, Barry Zvi Shapira, Roy Teruyuki Uyeda
  • Patent number: 6410586
    Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B. CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 25, 2002
    Assignees: Novo Nordisk A/S, Ontogen Corporation
    Inventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda